Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.
The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Clinical practices does not always reflect evidence-based expert opinion when it comes to management of acute or chronic myeloid leukemia (AML, CML) and B-cell lymphomas.
Ponatinib shows "early, deep and durable" molecular responses among patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Fludarabine, cyclophosphamide and rituximab (FCR) chemoimmunotherapy is associated with improved event-free survival in patients with high-risk, early-stage CLL.
Clinical activity has been observed in patients with relapsed/refractory CLL at all doses of IPI-145 studied, from 8 mg to 75 mg twice daily.
Ixazomib citrate plus lenalidomide/dexamethasone active in newly diagnosed multiple myeloma.
Adding gemtuzumab ozogamicin to standard therapy improved event-free survival improved in children with de novo acute myeloid leukemia.
Dendritic cell vaccination after chemotherapy-induced remission in acute myeloid leukemia has a "demonstrable" anti-relapse effect for some high-risk patient, according to data presented at ASH 2013.
CTL019 cells can induce potent and durable responses in children and adults with relapsed/refractory acute lymphoblastic leukemia, according to results of a pilot study reported at ASH 2013.
Obinutuzumab (GA101) plus chlorambucil significantly prolonged PFS in treatment-naïve patients with chronic lymphocytic leukemia and co-existing medical conditions, according to data presented at ASH 2013.
For adults with ALL, ex-vivo T-cell depleted allogenic HCT is associated with a lower rate of graft versus host disease than conventional, unmodified allografts, according to data presented at ASH 2013.
CTL019 T cells engineered to express chimeric antigen receptor, which targets CD19, show promise against advanced, refractory CLL and pediatric pre-B-cell ALL, according to research presented at ASH 2013.
Continuous treatment with lenalidomide and low-dose dexamethasone has been established as a new standard of care for patients with newly diagnosed multiple myeloma who are ineligible for SCT, according to data presented at ASH 2013.
Subcutaneous denosumab is associated with strong serum calcium responses among patients with hypercalcemia of malignancyfollowing IV bisphosphonate treatment, found research at ASH 2013.
Genetically modified donor-derived anti-CD19 CAR-expressing T-cell infusions were followed by regression of B-cell malignancies that had persisted after alloHSCT, according to research presented at ASH 2013.
Infusions of autologous T cells genetically modified to express a chimeric antigen receptor that targets B-cell antigen CD19 were associated with at least partial remissions in patients with chemotherapy-refractory diffuse large B-cell lymphoma, found research at ASH 2013.
Siltuximab improves symptoms and clinical outcomes for patients with multicentric Castleman's disease, despite a high rate of drug discontinuation due to toxicities, according to data presented at ASH 2013.
Bortezomib was associated with a low rate of grade 3 or higher heart failure in patients with multiple myeloma treated in upfront or relapsed and/or refractory settings, found research at ASH 2013.
Higher cumulative doses of bortezomib are associated with improved overall survival among patients with previously untreated multiple myeloma, found research presented at ASH 2013.
Rates of complete remission were promising in patients with FLT3-ITD-positive acute myeloid leukemia when midostaurin was added to intensive induction therapy, according to data presented at ASH 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified